David G Carroll

Address:

44 Brentwood Ave, San Francisco, CA 94127

Phone:

(415)5842281

VIN:

WBAEK13587CN84375

Make:

BMW

Model:

6 SERIES

Year:

2007

US Patent:

6563832, May 13, 2003

Filed:

Mar 10, 1999

Appl. No.:

09/266239

Inventors:

Carson Stuart - Chapel Hill NC
Kevin R. Lingle - Knightdale NC
Claude Alan Cartee - Los Altos CA
Eric Decker - Scotts Valley CA
David A. Carroll - Apex NC
Jeffrey W. Kidd - Hillsborough NC
Kara J. Adams - Raleigh NC
Randall G. Campbell - Durham NC

Assignee:

Cisco Technology, Inc. - San Jose CA

International Classification:

H04L 12417

US Classification:

370403, 370406, 370408

Abstract:

A distributed token ring (TR) bridge has a logical switch fabric that is distributed over a TR switching network of switches interconnected by trunk links. The distributed TR bridge includes a plurality of TR switches, each having a Bridge Relay Function (BRF) logically coupled to at least one Concentrator Relay Function (CRF). Distribution of the switch fabric essentially comprises logically distributing the BRF function among the network of switches.

US Patent:

6657951, Dec 2, 2003

Filed:

Mar 10, 1999

Appl. No.:

09/266198

Inventors:

David A. Carroll - Apex NC
John K. Fitzgerald - Cary NC
Kara J. Adams - Raleigh NC
Gary William Kramling - Raleigh NC

Assignee:

Cisco Technology, Inc. - San Jose CA

International Classification:

H04L 100

US Classification:

370222, 370225, 370244, 370245, 370248, 370250, 370400, 370434, 370445, 370452, 709220, 709229, 709239, 709249, 709251, 714 1

Abstract:

A backup CRF VLAN arrangement provides an alternate, redundant path for traffic between undistributed Concentrator Relay Functions (CRFs) located on separate switches interconnected by trunk links of a distributed token ring bridge. The backup CRF virtual local area network (VLAN) arrangement defines a backup network path which may be utilized if a primary active path is not a valid path to a backup network. Notably, the backup network comprises a special type of CRF that is distributed among the switches, but that has only one port active at any given time.

US Patent:

6674727, Jan 6, 2004

Filed:

Mar 10, 1999

Appl. No.:

09/266241

Inventors:

David A. Carroll - Apex NC
John K. Fitzgerald - Cary NC
Kara J. Adams - Raleigh NC
Gary William Kramling - Raleigh NC

Assignee:

Cisco Technology, Inc. - San Jose CA

International Classification:

H04L 12417

US Classification:

370254, 370403, 370410, 370476

Abstract:

A Distributed Ring Protocol (DRiP) arrangement includes a database and protocol for maintaining and distributing information within a distributed token ring (TR) bridge having a logical switch fabric that is distributed over a TR switching network of switches interconnected by trunk links, such as Inters witch Link (ISL) trunks. The DRiP information is used by switches within the ISL switched fabric to determine the status (configured and/or activated) and association (within a switch) of ports of the distributed bridge.

US Patent:

6704318, Mar 9, 2004

Filed:

Mar 10, 1999

Appl. No.:

09/265668

Inventors:

Carson Stuart - Chapel Hill NC
David A. Carroll - Apex NC
Jeffrey W. Kidd - Hillsborough NC
Kara J. Adams - Raleigh NC
Wayne Garavaglia - Woodside CA

Assignee:

Cisco Technology, Inc. - San Jose CA

International Classification:

H04L 1228

US Classification:

370403

Abstract:

A technique efficiently transports token ring (TR) frames over trunks interconnecting switches of a distributed TR bridge. The TR bridge is characterized by a logical switch fabric that is distributed among the interconnected switches by the trunks, which are preferably interswitch link (ISL) trunks. Each switch includes a Bridge Relay Function (BRF) coupled to a plurality of Concentrator Relay Functions (CRFs) having a plurality of ports for receiving TR frames over TR segments. The BRF and CRF of the distributed TR bridge operate according to a 2-tier switching model wherein each CRF and BRF is assigned an individual virtual local area network identifier. The technique encapsulates the TR frames in a TR-ISL protocol format that accomodates differences in formats of various TR frames and that comports with the 2-tier switching model of the distributed TR bridge.

US Patent:

7122542, Oct 17, 2006

Filed:

Jul 30, 2004

Appl. No.:

10/903870

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Hui Li - Millbrae CA, US
Somasekhar Bhamidipati - Foster City CA, US
David Carroll - San Francisco CA, US
Catherine Sylvain - Burligame CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 19/02
A61K 31/535
C07D 268/36

US Classification:

5142305, 544105

Abstract:

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

US Patent:

7452879, Nov 18, 2008

Filed:

Oct 5, 2006

Appl. No.:

11/539147

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Hui Li - Millbrae CA, US
Somasekhar Bhamidipati - Foster City CA, US
David Carroll - San Francisco CA, US
Catherine Sylvain - San Mateo CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07D 401/14
C07D 403/14
C07D 413/14
C07D 417/14
A61K 31/506
A61K 31/4523
A61K 31/5377
A61K 31/541
A61P 19/02
A61P 37/00

US Classification:

5142315, 514272, 514274, 51425213, 5142272, 51421001, 51421101, 51421201, 544320, 544323, 544324, 544111, 544 60, 540484, 540450

Abstract:

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

US Patent:

7482351, Jan 27, 2009

Filed:

Jun 29, 2005

Appl. No.:

11/171970

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
David Carroll - San Francisco CA, US
Tarikere Gururaja - Santa Clara CA, US
Taisei Kinoshita - San Mateo CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A01N 43/54
C07D 239/42
C07D 401/04
C07D 239/02

US Classification:

514256, 544326

Abstract:

The present disclosure provides 4-pyrimidineamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.

US Patent:

7491732, Feb 17, 2009

Filed:

Jun 8, 2006

Appl. No.:

11/450901

Inventors:

Hui Li - Santa Clara CA, US
David Carroll - San Francisco CA, US
Ankush Argade - Foster City CA, US
Robin Cooper - St. George Island FL, US
Rajinder Singh - Belmont CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07D 239/48
A61K 31/505

US Classification:

514275, 5142778, 5142358, 544 586, 544122, 544323

Abstract:

The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.